AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

Soon Khai Low; Suparna Nanua; Mehul Patel; Anne S Renteria

doi:10.1016/j.lrr.2022.100333

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

Leuk Res Rep. 2022 Jun 22:17:100333. doi: 10.1016/j.lrr.2022.100333. eCollection 2022.

Authors

Soon Khai Low¹, Suparna Nanua², Mehul Patel³, Anne S Renteria⁴

Affiliations

¹ Department of Internal Medicine, Rochester General Hospital, NY, United States.
² Department of Pathology, Rochester General Hospital, NY, United States.
³ Hematology Oncology, Lipson Cancer Institute, Rochester General Hospital, NY, United States.
⁴ Acute Leukemia & Stem Cell Transplant and Cellular Therapy Programs, Lipson Cancer Institute, Rochester General Hospital, NY, United States.

Abstract

A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytogenetic complete response despite additional cytogenetic and molecular abnormalities. She remains in remission after eleven cycles of treatment. Our report describes the tolerability and success of a triplet regimen that incorporates a TKI to a backbone of decitabine and venetoclax in a patient with high-risk disease and with significant comorbidities.

Keywords: Acute myeloid leukemia; Decitabine; Philadelphia chromosoome; Tyrosine kinase inhibitor; Venetoclax.

Publication types

Case Reports